Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferiprone proof-of-concept study in children with Pelizaeus-Merzbacher disease
NL-OMON27427Not yet recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of deferiprone in Pelizaeus-Merzbacher disease (PMD), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: Gross motor function. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
deferiprone
03
Conditions
Pelizaeus-Merzbacher disease (PMD)
Beyond the preview
Go deeper on NL-OMON27427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27427.